Viatris (VTRS) Gains from Investment Securities (2020 - 2026)
Viatris (VTRS) recorded quarterly Gains from Investment Securities of $82.0 million in Q1 2026, up 1476.92% quarter-over-quarter from $5.2 million in Q4 2025, and up 140.24% on a YoY basis from $34.1 million in Q1 2025.
Viatris (VTRS) Gains from Investment Securities (2020 - 2026) Analysis & Trends
Viatris' Gains from Investment Securities history runs 7 years deep, the most recent figure standing at $82.0 million for Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 140.24% year-over-year to $82.0 million; the TTM figure through Mar 2026 stood at $321.3 million (up 274.62% YoY), while the FY2025 annual figure was $35.5 million, up 70.67% from the prior year.
- Gains from Investment Securities was $82.0 million for Q1 2026 at Viatris, up from $5.2 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $756.6 million in Q3 2025 to a low of -$522.5 million in Q2 2025.
- Historically, Gains from Investment Securities has averaged -$11.7 million across 5 years, with a median of $9.9 million in 2022.
- The sharpest annual moves came in 2023 and 2025: Gains from Investment Securities surged 1706.06% in 2023, then tumbled 20480.0% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at -$459.1 million in 2022, then soared by 109.89% to $45.4 million in 2023, then plunged by 451.98% to -$159.8 million in 2024, then soared by 103.25% to $5.2 million in 2025, then surged by 1476.92% to $82.0 million in 2026.
- The last three Gains from Investment Securities figures came in at $82.0 million (Q1 2026), $5.2 million (Q4 2025), and $756.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn |
| 10 | Viatris | - | - | 1.16 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 82.00 Mn |
| Mar 31, 2026 | 82.00 Mn |
| Dec 31, 2025 | 5.20 Mn |
| Dec 31, 2025 | 5.20 Mn |
| Sep 30, 2025 | 756.60 Mn |
| Sep 30, 2025 | 756.60 Mn |
| Jun 30, 2025 | -522.50 Mn |
| Jun 30, 2025 | -522.50 Mn |
| Mar 31, 2025 | -203.80 Mn |
| Mar 31, 2025 | -203.80 Mn |
| Dec 31, 2024 | -159.80 Mn |
| Dec 31, 2024 | -159.80 Mn |
| Sep 30, 2024 | 168.90 Mn |
| Sep 30, 2024 | 168.90 Mn |
| Jun 30, 2024 | 10.70 Mn |
| Jun 30, 2024 | 10.70 Mn |
| Mar 31, 2024 | 1.00 Mn |
| Mar 31, 2024 | 1.00 Mn |
| Dec 31, 2023 | 45.40 Mn |
| Dec 31, 2023 | 45.40 Mn |